Value-Based Kidney Care:
A New Approach to Screening

How payers can improve outcomes
with smartphone-powered kidney testing
Download

Download the White Paper

37M Americans are living with chronic kidney disease, yet the majority remain undiagnosed. Although a simple urine test can provide an early warning for the disease during its asymptomatic stages, only 20% of people at risk take their albumin-to-creatinine ratio (ACR) test.

A new approach to kidney screening using smartphone-powered home testing can help raise adherence, improve health outcomes and reduce the cost of care. Download this white paper to learn:

  • Why ACR is a vital missing metric
  • The crucial difference between ACR urine tests and eGFR blood tests
  • The health and economic impact of home testing
By providing this information, you consent to receive relevant content from Healthy.io. For more information, visit our Privacy Policy.
By providing this information, you consent to receive relevant content from Healthy.io. For more information, visit our Privacy Policy.